J
John T. Hamm
Researcher at Norton Healthcare
Publications - 67
Citations - 6968
John T. Hamm is an academic researcher from Norton Healthcare. The author has contributed to research in topics: Chemotherapy & Cancer. The author has an hindex of 20, co-authored 57 publications receiving 6567 citations. Previous affiliations of John T. Hamm include University of Louisville.
Papers
More filters
Journal ArticleDOI
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
Malcolm J. Moore,David Goldstein,John T. Hamm,Arie Figer,J. R. Hecht,Steven Gallinger,Heather J. Au,Pawel Murawa,David Walde,Robert A. Wolff,D. M. B. Campos,Robert Lim,Keyue Ding,Gary M. Clark,Theodora Voskoglou-Nomikos,Mieke Ptasynski,Wendy R. Parulekar +16 more
TL;DR: To the authors' knowledge, this randomized phase III trial is the first to demonstrate statistically significantly improved survival in advanced pancreatic cancer by adding any agent to gemcitabine.
Journal ArticleDOI
2000 Update of Recommendations for the Use of Hematopoietic Colony-Stimulating Factors: Evidence-Based, Clinical Practice Guidelines*
Thomas J. Smith,Howard Ozer,Langdon L. Miller,Charles A. Schiffer,Rodger J. Winn,James R. Anderson,Paul N. Anderson,James O. Armitage,Stacey Beckhardt,Charles L. Bennett,Gerald P. Bodey,Jeffrey Crawford,Nancy E. Davidson,George D. Demetri,John T. Hamm,Bruce E. Hillner,Carl G. Kardinal,Mark Levine,John A. Miller,Judith Ochs,Victor M. Santana,Thomas C. Shea,Saroj Vadhan-Raj,James L. Wade,Jane C. Weeks +24 more
Journal ArticleDOI
Addition of Bevacizumab to Bolus Fluorouracil and Leucovorin in First-Line Metastatic Colorectal Cancer: Results of a Randomized Phase II Trial
Fairooz F. Kabbinavar,J. Schulz,Michael McCleod,Taral Patel,John T. Hamm,J. Randolph Hecht,Robert D. Mass,Brent Perrou,B. Nelson,William Novotny +9 more
TL;DR: Addition of bevacizumab to FU/LV as first-line therapy in CRC patients who were not considered optimal candidates for first- line irinotecan treatment provided clinically significant patient benefit, including statistically significant improvement in progression-free survival.
Journal ArticleDOI
Further Evaluation of Intensified and Increased Total Dose of Cyclophosphamide for the Treatment of Primary Breast Cancer: Findings From National Surgical Adjuvant Breast and Bowel Project B-25
Bernard Fisher,Stewart J. Anderson,Arthur DeCillis,Nikolay V. Dimitrov,James N. Atkins,Louis Fehrenbacher,Patrick H. Henry,Edward H. Romond,Keith S. Lanier,Enrique Davila,Carl G. Kardinal,Leslie R. Laufman,H. Irving Pierce,Neil Abramson,Alan Keller,John T. Hamm,D L Wickerham,Mirsada Begovic,Elizabeth Tan-Chiu,Wei Tian,Norman Wolmark +20 more
TL;DR: Because intensifying and increasing cyclophosphamide two or four times that given in standard clinical practice did not substantively improve outcome, such therapy should be reserved for the clinical trial setting.
Journal ArticleDOI
Clinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: results of a worldwide expanded access program study
Brian L. Samuels,Shanta Chawla,Shreyaskumar Patel,M. von Mehren,John T. Hamm,Pamela E. Kaiser,Scott M. Schuetze,J. Li,A. Aymes,George D. Demetri +9 more
TL;DR: Results of this EAP are consistent with previous reports of trabectedin, demonstrating disease control despite a low incidence of objective responses in advanced STS patients after failure of standard chemotherapy.